Wednesday, October 19, 2016 3:22:26 PM
The billion dollar drug hit the market in 2017. This is faster even than most of well known bios trading 500m and north. cpxx ran 2600%,this year, to over 1B cap while ktov actually beats her: much better balance sheet, zero debt, higher sales prediction, better SS and both should hit the market in 2017 .KTOV trading on a joke market cap of only $28m right now.
CPXX sales prediction: $750m(US+EU) vs KTOV $1B(US alone, Blockbaster potential per Rodman & Renshaw and per LifeSci Capital,$513 M by year 2022, us alone-not including EU market and rest of the World, recent KTOV slides "We estimate that KIT-302 has the potential to save US healthcare system ~ $650M annually").
Phase 3 completed on both. Marketing approval expected for both- 2017.
Market cap: CPXX: $1.1B vs KTOV $28M.
Cash&Debt: CPXX $23M in Cash, $19M Debt vs KTOV $21M in Cash, Zero Debt.
there is no competition between these companies, completely different drugs & market potential. Comparison made just to show major parameters like sales prediction, market cap, market potential, balance sheet...
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM